These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 1374791)

  • 61. Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes.
    Larder BA; Kellam P; Kemp SD
    AIDS; 1991 Feb; 5(2):137-44. PubMed ID: 1709563
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Variations in reverse transcriptase and RNase H domain mutations in human immunodeficiency virus type 1 clinical isolates are associated with divergent phenotypic resistance to zidovudine.
    Ntemgwa M; Wainberg MA; Oliveira M; Moisi D; Lalonde R; Micheli V; Brenner BG
    Antimicrob Agents Chemother; 2007 Nov; 51(11):3861-9. PubMed ID: 17724152
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Zidovudine-resistant human immunodeficiency virus type 1 genomes detected in plasma distinct from viral genomes in peripheral blood mononuclear cells.
    Smith MS; Koerber KL; Pagano JS
    J Infect Dis; 1993 Feb; 167(2):445-8. PubMed ID: 7678429
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Phenotypic mechanism of HIV-1 resistance to 3'-azido-3'-deoxythymidine (AZT): increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase.
    Arion D; Kaushik N; McCormick S; Borkow G; Parniak MA
    Biochemistry; 1998 Nov; 37(45):15908-17. PubMed ID: 9843396
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Zidovudine resistance is suppressed by mutations conferring resistance of human immunodeficiency virus type 1 to foscarnet.
    Tachedjian G; Mellors J; Bazmi H; Birch C; Mills J
    J Virol; 1996 Oct; 70(10):7171-81. PubMed ID: 8794364
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Rapid CD4+ cell decline after sexual transmission of a zidovudine-resistant syncytium-inducing isolate of HIV-1.
    Kuritzkes DR; Bell S; Bakhtiari M
    AIDS; 1994 Jul; 8(7):1017-9. PubMed ID: 7524542
    [No Abstract]   [Full Text] [Related]  

  • 67. Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].
    Taylor DL; Ahmed PS; Tyms AS; Wood LJ; Kelly LA; Chambers P; Clarke J; Bedard J; Bowlin TL; Rando RF
    Antivir Chem Chemother; 2000 Jul; 11(4):291-301. PubMed ID: 10950391
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Studies of the resistance of the human immunodeficiency virus to azidothymidine. I. Kinetic studies of the interaction between reverse transcriptase and a series of its mutant forms with substrates and azidothymidine-5'-trisphosphate].
    Pokholok DK; Gudima SO; Esipov DS; Dobrynin VN; Memelova LV; Rechinskiĭ VO; Kochetkov SN
    Biokhimiia; 1994 May; 59(5):739-47. PubMed ID: 7519060
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Phosphorylation of AZT-resistant human immunodeficiency virus type 1 reverse transcriptase by casein kinase II in vitro: effects on inhibitor sensitivity.
    Lazaro JB; Boretto J; Selmi B; Capony JP; Canard B
    Biochem Biophys Res Commun; 2000 Aug; 275(1):26-32. PubMed ID: 10944435
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Natural residues versus antiretroviral drug-selected mutations in HIV type 1 group O reverse transcriptase and protease related to virological drug failure in vivo.
    de Baar MP; Janssens W; de Ronde A; Fransen K; Colebunders R; Kestens L; van der Groen G; Goudsmit J
    AIDS Res Hum Retroviruses; 2000 Sep; 16(14):1385-94. PubMed ID: 11018858
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Long-term persistence of zidovudine resistance mutations in plasma isolates of human immunodeficiency virus type 1 of dideoxyinosine-treated patients removed from zidovudine therapy.
    Smith MS; Koerber KL; Pagano JS
    J Infect Dis; 1994 Jan; 169(1):184-8. PubMed ID: 7506280
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Mutations in the HIV type 1 integrase of patients receiving long-term dideoxynucleoside therapy do not confer resistance to zidovudine.
    Pilon AA; Marchand C; Kavlick MF; Bajaj K; Owen J; Mitsuya H; Pommier Y
    AIDS Res Hum Retroviruses; 2000 Sep; 16(14):1417-22. PubMed ID: 11018861
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Prevalence of primary resistance to zidovudine and lamivudine in drug-naive human immunodeficiency virus type-1 infected patients: high proportion of reverse transcriptase codon 215 mutant in circulating lymphocytes and free virus.
    Trabaud MA; Leriche-Guerin K; Regis C; Bordes I; Cotte L; Detmer J; Kolberg J; Ritter J; Trépo C
    J Med Virol; 2000 Jul; 61(3):352-9. PubMed ID: 10861645
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Combination therapy with zidovudine prevents selection of human immunodeficiency virus type 1 variants expressing high-level resistance to L-697,661, a nonnucleoside reverse transcriptase inhibitor.
    Staszewski S; Massari FE; Kober A; Göhler R; Durr S; Anderson KW; Schneider CL; Waterbury JA; Bakshi KK; Taylor VI
    J Infect Dis; 1995 May; 171(5):1159-65. PubMed ID: 7538547
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Molecular aspect of HIV-1 resistance to zidovudine and its reversal.
    Camsonne R; Bigot MC; Bustany P; Pottier D; Vergnaud M
    Trends Pharmacol Sci; 1994 May; 15(5):137-8. PubMed ID: 7538701
    [No Abstract]   [Full Text] [Related]  

  • 76. HIV-1 sensitivity to zidovudine: a consensus culture technique validated by genotypic analysis of the reverse transcriptase.
    Brun-Vézinet F; Ingrand D; Deforges L; Gochi K; Ferchal F; Schmitt MP; Jung M; Masquelier B; Aubert J; Buffet-Janvresse C
    J Virol Methods; 1992 May; 37(2):177-88. PubMed ID: 1375948
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Zidovudine-resistant human immunodeficiency virus selected by passage in cell culture.
    Larder BA; Coates KE; Kemp SD
    J Virol; 1991 Oct; 65(10):5232-6. PubMed ID: 1716689
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Detection of human immunodeficiency virus type 1 clinical isolates with reduced sensitivity to zidovudine and dideoxyinosine by RNA.RNA hybridization.
    Japour AJ; Chatis PA; Eigenrauch HA; Crumpacker CS
    Proc Natl Acad Sci U S A; 1991 Apr; 88(8):3092-6. PubMed ID: 1707532
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Difference of virus populations in HIV carriers in relation to AZT treatment.
    Sakamoto T; Wakamiya N; Tochikura A; Tsuchie H; Kurimura T
    Int J STD AIDS; 1997 Jun; 8(6):378-81. PubMed ID: 9179648
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Molecular aspects of AZT resistance in HIV1.
    Levantis P; Oxford JS
    Res Virol; 1992; 143(2):136-42. PubMed ID: 1594798
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.